Cover Image
市場調查報告書

血漿蛋白質治療藥市場 - 全球產業分析,規模,佔有率,成長,趨勢及預測

Plasma Protein Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

出版商 Transparency Market Research 商品編碼 367377
出版日期 內容資訊 英文 139 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
血漿蛋白質治療藥市場 - 全球產業分析,規模,佔有率,成長,趨勢及預測 Plasma Protein Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
出版日期: 2016年07月15日 內容資訊: 英文 139 Pages
簡介

血漿蛋白質治療藥的使用在醫療領域展現大幅擴展。對高齡化,以及新適應的使用,新的血漿來歷的治療藥的開發等推進著市場擴大。

本報告提供全球血漿蛋白質治療藥市場相關調查,市場現狀及未來發展預測,各產品,地區趨勢,參與企業簡介等彙整資料。

第1章 序論

第2章 摘要整理

第3章 產業分析

  • 簡介
  • 法律規章方案
  • 市場趨勢
    • 促進要素
    • 阻礙要素
    • 機會
  • 市場魅力度分析
  • 波特五力分析
  • 市場收益:各產品
  • 市場收益:各用途
  • 競爭環境

第4章 北美市場分析

  • 各產品市場收益
  • 各用途市場收益
  • 各國市場收益

第5章 歐洲市場分析

  • 各產品市場收益
  • 各用途市場收益
  • 各國市場收益

第6章 亞太地區市場分析

  • 各產品市場收益
  • 各用途市場收益
  • 各國市場收益

第7章 南美市場分析

  • 各產品市場收益
  • 各用途市場收益
  • 各國市場收益

第8章 其他的市場分析

  • 各產品市場收益
  • 各用途市場收益

第9章 企業簡介

  • Baxter International
  • Biotest
  • CSL Behring
  • China Biologics
  • GRIFOLS, S.A.
  • Kedrion
  • Octapharma USA, Inc.
  • Shire Plc.

圖表

目錄

The use of plasma protein therapeutics has significantly increased in medical applications. This, coupled with the rising aging population, its medicinal use in novel indications, and the advent of new plasma-derived therapies, has been propelling the market for plasma protein therapeutics. Transparency Market Research (TMR) projects the market to continue exhibiting robust growth worldwide between 2016 and 2024.

Recent advancements introduced in plasma protein therapeutics aimed at improving the quality of patient care have been pivotal in fuelling their demand. These advancements have also proven crucial in guaranteeing donor's safety. The increasing demand for immunoglobulin (IG) and the increasing use of protein therapeutics will thus augment demand for plasma protein therapeutics. TMR expects, the global market for the same to rise at a CAGR of 7.0% between 2016 and 2024. The market stood at US$18.5 bn in 2015 and is expected to reach US$31.84 bn by the end of 2024. Despite exhibiting growth at a positive rate, stringent regulations and lack of proper reimbursement policies could hamper the market's trajectory.

XX Commercial in Confidence.

North America, trailed by Europe, Exhibits Most Lucrative Prospects for Market

Regionally, North America, Asia Pacific, Europe, Latin America, and Rest of the World constitute the most lucrative markets for plasma protein therapeutics. Among these regions, North America held the dominant share in the global market in 2015, trailed by Europe. New indications, the increasing geriatric population, and investments in novel researches are boosting prospects for the market in North America. As per TMR, the North America plasma protein therapeutics market is expected to reach US$13.8 bn by the end of 2024 from a valuation of US$7.5 bn in 2015. If the figures hold true, the regional market will exhibit a CAGR of 7.9% during the forecast period.

In Europe, demand for protein therapeutics is increasing consequent to the rise in the number of clinical indications for immunoglobulin. Since immunoglobulin finds application across hematology, neurology, dermatology, nephrology, immunology, ophthalmology, rheumatology, and others, demand for protein therapeutics in Europe is expected to remain high.

During the forecast period, TMR projects Asia Pacific to emerge as the most lucrative market for plasma protein therapeutics. The rising demand for albumin and immunoglobulin in Asia Pacific is bolstering prospects for expansion of the market in the region. Furthermore, the region is also known to import albumin and immunoglobulin from North America and Europe. China as per TMR, imports nearly half of its albumin supply in order to bridge the demand and supply gap. The albumin segment is thus expected to register the fastest growth in Asia Pacific. In Latin America, however, the plasma protein therapeutics market is restrained by low rate of diagnosis and treatment and high pricing.

<

>Growth to be Facilitated by Rising Incidence of Immunodeficiency Disorders

Plasma protein therapeutics is increasingly used in the treatment of primary immunodeficiency disorder (PID). The PID segment is likely to exhibit a CAGR of 7.6% between 2015 and 2024. The PID treatment segment is poised to gain considerably from the increasing investment immunoglobulin. Furthermore, with the increasing incidence of secondary immunodeficiency disorders, applications of plasma protein therapeutics is likely to increase across the treatment of prolonged illnesses. The most common secondary immunodeficiency disorders include diabetes, myeloma, HIV infection, and under-nutrition. Despite being a rare disorder, treatment of hereditary angioedema (HAE) has become possible due to the growing awareness regarding the disease worldwide. This is expected to boost the demand for plasma protein therapeutics significantly.

Some of the leading players operating in the global plasma protein therapeutics market include:

Baxter International, Biotest, CSL Behring, Grifols, S.A., Kedrion, Octapharma USA, Inc., Shire plc, and China Biologics.

Table of Contents

Chapter 1 - Preface

  • 1.1. Report Description
  • 1.2. Market Segmentation
  • 1.3. Research Methodology

Chapter 2 - Executive Summary

  • 2.1. Global Plasma Protein Therapeutics Market Snapshot

Chapter 3 - Global Plasma Protein Therapeutics Market Revenue Analysis, 2014-2024 (US$ Mn)

  • 3.1. Introduction
  • 3.2. Regulatory Scenario
  • 3.3. Market Dynamics
    • 3.3.1. Drivers
    • 3.3.2. Restraints
    • 3.3.3. Opportunity
  • 3.4. Market Attractiveness Analysis, by Region, 2015
  • 3.5. Porter's Five Forces Analysis
  • 3.6. Global Plasma Protein Therapeutics Market Revenue Analysis, By Product Type, 2014-2024 (US$ Mn)
    • 3.6.1. Global Immunoglobulins Market Revenue, 2014-2024 (US$ Mn)
    • 3.6.2. Global Albumin Market Revenue, 2014-2024 (US$ Mn)
    • 3.6.3. Global Coagulation Factors Market Revenue, 2014-2024 (US$ Mn)
    • 3.6.4. Global C1-esterase Inhibitors Market Revenue, 2014-2024 (US$ Mn)
    • 3.6.5. Others (e.g. Alpha-1 Proteinase Inhibitors, Hyperimmune Globulins)
  • 3.7. Global Plasma Protein Therapeutics Market Analysis, By Application, 2014-2024 (US$ Mn)
    • 3.7.1. Global Hemophilia Market Revenue, 2014-2024 (US$ Mn)
    • 3.7.2. Global Primary Immunodeficiency Disorder (PID) Market Revenue, 2014-2024 (US$ Mn)
    • 3.7.3. Global Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2014-2024 (US$ Mn)
    • 3.7.4. Global Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, Congenital AIDS, etc.) Market Revenue, 2014-2024 (US$ Mn)
    • 3.7.5. Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
  • 3.8. Competitive Landscape
    • 3.8.1. Market Positioning of Key Players, 2015
    • 3.8.2. Recommendations
  • 3.9. Pipeline Analysis
    • 3.9.1. Phase 1 and Phase 2 Drugs (Qualitative Analyses)
    • 3.9.2. Phase 3 and Phase 4 Drugs (Quantitative), Forecasts till 2024

Chapter 4 - North America Plasma Protein Therapeutics Market Revenue Analysis, 2014-2024 (US$ Mn)

  • 4.1. North America Plasma Protein Therapeutics Market Revenue, By Product Type, 2014-2024 (US$ Mn)
    • 4.1.1. North America Immunoglobulins Market Revenue, 2014-2024 (US$ Mn)
    • 4.1.2. North America Albumin Market Revenue, 2014-2024 (US$ Mn)
    • 4.1.3. North America Coagulation Factors Market Revenue, 2014-2024 (US$ Mn)
    • 4.1.4. North America C1-esterase Inhibitors Market Revenue, 2014-2024 (US$ Mn)
    • 4.1.5. Others
  • 4.2. North America Plasma Protein Therapeutics Market Revenue, By Application, 2014-2024 (US$ Mn)
    • 4.2.1. North America Hemophilia Market Revenue, 2014-2024 (US$ Mn)
    • 4.2.2. North America Primary Immunodeficiency Disorder (PID) Market Revenue, 2014-2024 (US$ Mn)
    • 4.2.3. North America Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2014-2024 (US$ Mn)
    • 4.2.4. North America Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, and Congenital AIDS, etc.) Market Revenue, 2014-2024 (US$ Mn)
    • 4.2.5. Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
  • 4.3. North America Plasma Protein Therapeutics Market Revenue, by Country 2014-2024 (US$ Mn)

Chapter 5 - Europe Plasma Protein Therapeutics Market Revenue, 2014-2024 US$ Mn)

  • 5.1. Europe Plasma Protein Therapeutics Market Revenue, By Product Type, 2014-2024 (US$ Mn)
    • 5.1.1. Europe Immunoglobulins Market Revenue, 2014-2024 (US$ Mn)
    • 5.1.2. Europe Albumin Market Revenue, 2014-2024 (US$ Mn)
    • 5.1.3. Europe Coagulation Factors Market Revenue, 2014-2024 (US$ Mn)
    • 5.1.4. Europe C1-esterase Inhibitors Market Revenue, 2014-2024 (US$ Mn)
    • 5.1.5. Others
  • 5.2. Europe Plasma Protein Therapeutics Market Revenue, By Application, 2014-2024 (US$ Mn)
    • 5.2.1. Europe Hemophilia Market Revenue, 2014-2024 (US$ Mn)
    • 5.2.2. Europe Primary Immunodeficiency Disorder (PID) Market Revenue, 2014-2024 (US$ Mn)
    • 5.2.3. Europe Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2014-2024 (US$ Mn)
    • 5.2.4. Europe Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, Congenital AIDS, etc.) Market Revenue, 2014-2024 (US$ Mn)
    • 5.2.5. Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
  • 5.3 Europe Plasma Protein Therapeutics Market Revenue, by Country, 2014-2024 (US$ Mn)

Chapter 6 - Asia Pacific Plasma Protein Therapeutics Market Revenue Analysis, 2014-2024 (US$ Mn)

  • 6.1. Asia Pacific Plasma Protein Therapeutics Market Revenue, By Product Type, 2014-2024 (US$ Mn)
    • 6.1.1. Asia Pacific Immunoglobulins Market Revenue, 2014-2024 (US$ Mn)
    • 6.1.2. Asia Pacific Albumin Market Revenue, 2014-2024 (US$ Mn)
    • 6.1.3. Asia Pacific Coagulation Factors Market Revenue, 2014-2024 (US$ Mn)
    • 6.1.4. Asia Pacific C1-esterase inhibitors Market Revenue, 2014-2024 (US$ Mn)
    • 6.1.5. Others
  • 6.2. Asia Pacific Plasma Protein Therapeutics Market Revenue, By Application, 2014-2024 (US$ Mn)
    • 6.2.1. Asia Pacific Hemophilia Market Revenue, 2014-2024 (US$ Mn)
    • 6.2.2. Asia Pacific Primary Immunodeficiency Disorder (PID) Market Revenue, 2014-2024 (US$ Mn)
    • 6.2.3. Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2014-2024 (US$ Mn)
    • 6.2.4. Asia Pacific Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, and Congenital AIDS, etc.) Market Revenue, 2014-2024 (US$ Mn)
    • 6.2.5. Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
  • 6.3. Asia Pacific Plasma Protein Therapeutics Market by Geography, Market Revenue, 2014-2024 (US$ Mn)

Chapter 7 - Latin America Plasma Protein Therapeutics Revenue Analysis, 2014-2024 (US$ Mn)

  • 7.1. Latin America Plasma Protein Therapeutics Market Revenue Analysis, By Product Type, 2014-2024 (US$ Mn)
    • 7.1.1. Latin America Immunoglobulins Market Revenue, 2014-2024 (US$ Mn)
    • 7.1.2. Latin America Albumin Market Revenue, 2014-2024 (US$ Mn)
    • 7.1.3. Latin America Coagulation Factors Market Revenue, 2014-2024 (US$ Mn)
    • 7.1.4. Latin America C1-esterase Inhibitors Market Revenue, 2014-2024 (US$ Mn)
    • 7.1.5. Others
  • 7.2. Latin America Plasma Protein Therapeutics Market Revenue, By Application, 2014-2024 (US$ Mn)
    • 7.2.1. Latin America Hemophilia Market Revenue, 2014-2024 (US$ Mn)
    • 7.2.2. Latin America Primary Immunodeficiency Disorder (PID) Market Revenue, 2014-2024 (US$ Mn)
    • 7.2.3. Latin America Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2014-2024 (US$ Mn)
    • 7.2.4. Latin America Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, and Congenital AIDS, etc.) Market Revenue, 2014-2024 (US$ Mn)
    • 7.2.5. Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
  • 7.3. Latin America Plasma Protein Therapeutics Market by Geography, Market Revenue, 2014-2024 (US$ Mn)

Chapter 8 - Rest of the World (RoW) Plasma Protein Therapeutics Market Revenue Analysis, 2014-2024 (US$ Mn)

  • 8.1. Rest of World Plasma Protein Therapeutics Market Revenue Analysis, By Product Type, 2014-2024 (US$ Mn)
  • 8.2. Rest of World Plasma Protein Therapeutics Market Revenue, By Application, 2014-2024 (US$ Mn)

Chapter 9 - Company Profiles

  • 9.1. Baxter International
    • 9.1.1. Company Overview
    • 9.1.2. Product Portfolio
    • 9.1.3. Financial Overview
    • 9.1.4. Business Strategies
    • 9.1.5. Recent Development
  • 9.2. Biotest
    • 9.2.1. Company Overview
    • 9.2.2. Product Portfolio
    • 9.2.3. Financial Overview
    • 9.2.4. Recent Development
  • 9.3. CSL Behring
    • 9.3.1. Company Overview
    • 9.3.2. Product Portfolio
    • 9.3.3. Financial Overview
    • 9.3.4. Business Strategies
    • 9.3.5. Recent Development
  • 9.4. China Biologics
    • 9.4.1. Company Overview
    • 9.4.2. Product Portfolio
    • 9.4.3. Financial Overview
    • 9.4.4. Business Strategies
    • 9.4.5. Recent Development
  • 9.5. GRIFOLS, S.A.
    • 9.5.1. Company Overview
    • 9.5.2. Product Portfolio
    • 9.5.3. Financial Overview
    • 9.5.4. Business Strategies
    • 9.5.5. Recent Development
  • 9.6. Kedrion
    • 9.6.1. Company Overview
    • 9.6.2. Product Portfolio
    • 9.6.3. Financial Overview
    • 9.6.4. Recent Development
  • 9.7. Octapharma USA, Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Product Portfolio
    • 9.7.3. Financial Overview
    • 9.7.4. Recent Development
  • 9.8. Shire Plc.
    • 9.8.1. Company Overview
    • 9.8.2. Product Portfolio
    • 9.8.3. Financial Overview
    • 9.8.4. Business Strategies
    • 9.8.5. Recent Development

List of Figures

  • FIG. 1: Global Plasma Protein Therapeutics Market Revenue, (US$ Mn), 2014-2024.
  • FIG. 2: Global Plasma Protein Therapeutics Market Revenue, by Product Type (US$ Mn), 2014-2024
  • FIG. 3: Global Plasma Protein Therapeutics Market Revenue, by Application (US$ Mn), 2014-2024
  • FIG. 4: Global Plasma Protein Therapeutics Market, by Geography (%), 2015
  • FIG. 5: Global Plasma Protein Therapeutics Market, by Geography (%), 2024
  • FIG. 6: Market Attractiveness Analysis, by Geography (2015)
  • FIG. 7: Porter's Five Forces Analysis
  • FIG. 8: Global Immunoglobulin Market Revenue, (US$ Mn), 2014-2024
  • FIG. 9: Global Albumin Market Revenue, (US$ Mn), 2014-2024
  • FIG. 10: Global Coagulation Factor Market Revenue, (US$ Mn), 2014-2024
  • FIG. 11: Global C1 Esterase Inhibitors Market Revenue, (US$ Mn), 2014-2024
  • FIG. 12: Other Plasma-derived Proteins Market Revenue, (US$ Mn), 2014-2024
  • FIG. 13: Global Hemophilia Market Revenue, (US$ Mn), 2014-2024
  • FIG. 14: Global Primary Immunodeficiency Disorder (PID) Market Revenue, (US$ Mn), 2014-2024
  • FIG. 15: Global Idiopathic Thrombocytopenic Purpura Market Revenue, (US$ Mn), 2014-2024
  • FIG. 16: Global Secondary Immunodeficiency Market Revenue, (US$ Mn), 2014-2024
  • FIG. 17: Global Hereditary Angioedema Market Revenue, (US$ Mn), 2014-2024
  • FIG. 18: Other Application Market Revenue, (US$ Mn), 2014-2024
  • FIG. 19: Market Positioning of Key Players, 2015
  • FIG. 20: North America Immunoglobulin Market Revenue, (US$ Mn), 2014-2024
  • FIG. 21: North America Albumin Market Revenue, (US$ Mn), 2014-2024
  • FIG. 22: North America Coagulation Factor Market Revenue, (US$ Mn), 2014-2024
  • FIG. 23: North America C1 Esterase Inhibitors Market Revenue, (US$ Mn), 2014-2024
  • FIG. 24: North America Primary Immunodeficiency Disorder (PID) Market Revenue, (US$ Mn), 2014-2024
  • FIG. 25: North America Idiopathic Thrombocytopenic Purpura Market Revenue, (US$ Mn), 2014-2024
  • FIG. 26: North America Secondary Immunodeficiency Market Revenue, (US$ Mn), 2014-2024
  • FIG. 27: Europe Immunoglobulin Market Revenue, (US$ Mn), 2014-2024
  • FIG. 28: Europe Albumin Market Revenue, (US$ Mn), 2014-2024
  • FIG. 29: Europe Coagulation Factor Market Revenue, (US$ Mn), 2014-2024
  • FIG. 28: Europe C1 Esterase Inhibitors Market Revenue, (US$ Mn), 2014-2024
  • FIG. 29: Europe Primary Immunodeficiency Disorder (PID) Market Revenue, (US$ Mn), 2014-2024
  • FIG. 30: Europe Idiopathic Thrombocytopenic Purpura Market Revenue, (US$ Mn), 2014-2024
  • FIG. 31: Europe Secondary Immunodeficiency Market Revenue, (US$ Mn), 2014-2024
  • FIG. 32: Asia Pacific Immunoglobulin Market Revenue, (US$ Mn), 2014-2024
  • FIG. 33: Asia Pacific Albumin Market Revenue, (US$ Mn), 2014-2024
  • FIG. 34: Asia Pacific Coagulation Factor Market Revenue, (US$ Mn), 2014-2024
  • FIG. 35: Asia Pacific C1 Esterase Inhibitors Market Revenue, (US$ Mn), 2014-2024
  • FIG. 36: Asia Pacific Primary Immunodeficiency Disorder (PID) Market Revenue, (US$ Mn), 2014-2024
  • FIG. 37: Asia Pacific Idiopathic Thrombocytopenic Purpura Market Revenue, (US$ Mn), 2014-2024
  • FIG. 38: Asia Pacific Secondary Immunodeficiency Market Revenue, (US$ Mn), 2014-2024
  • FIG. 39: LATAM Immunoglobulin Market Revenue, (US$ Mn), 2014-2024
  • FIG. 40: LATAM Albumin Market Revenue, (US$ Mn), 2014-2024
  • FIG. 41: LATAM Coagulation Factor Market Revenue, (US$ Mn), 2014-2024
  • FIG. 42: LATAM C1 Esterase inhibitors Market Revenue, (US$ Mn), 2014-2024
  • FIG. 43: LATAM Primary Immunodeficiency Disorder (PID) Market Revenue, (US$ Mn), 2014-2024
  • FIG. 44: LATAM Idiopathic Thrombocytopenic Purpura Market Revenue, (US$ Mn), 2014-2024
  • FIG. 45: LATAM Secondary Immunodeficiency Market Revenue, (US$ Mn), 2014-2024
  • FIG. 46: Baxter International Segmental Financial Overview: 2013-2015 (US$ Mn)
  • FIG. 47: Baxter International Geographical Financial Overview: 2013-2015 (US$ Mn)
  • FIG. 48: Biotest Financial Overview: 2013-2015 (US$ Mn)
  • FIG. 49: CSL Behring Segmental Financial Overview: 2013-2015 (US$ Mn)
  • FIG. 50: CSL Behring Geographical Financial Overview: 2013-2015 (US$ Mn)
  • FIG. 51: China Biologics Segmental Financial Overview: 2013-2015 (US$ Mn)
  • FIG. 52: GRIFOLS, S.A. Segmental Financial Overview: 2013-2015 (US$ Mn)
  • FIG. 53: GRIFOLS, S.A. Geographical Financial Overview: 2013-2015 (US$ Mn)
  • FIG. 54: Kedrion Financial Overview: 2012-2014 (US$ Mn)
  • FIG. 55: Octapharma USA, Inc. Financial Overview: 2012-2014 (US$ Mn)
  • FIG. 56: Shire Plc. Segmental Financial Overview: 2013-2015 (US$ Mn)
  • FIG. 57: Shire Plc. Geographical Financial Overview: 2013-2015 (US$ Mn)

List of Tables

  • Table 1: Plasma Protein Therapeutics Market Snapshot
  • Table 2: Global Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2014-2024
  • Table 3: Global Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2014-2024
  • Table 4: Global Plasma Protein Therapeutics Market Revenue, by Region, (US$ Mn), 2014-2024
  • Table 5: Pipeline Analysis (Phase I and Phase II)
  • Table 6: Pipeline Analysis (Phase III): Plasma protein Therapeutics, Expected Launch date of Approval to 2024 (US$ Mn)
  • Table 7: North America Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2014-2024
  • Table 8: North America Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2014-2024
  • Table 9: North America Plasma Protein Therapeutics Market Revenue, by Countries, (US$ Mn), 2014-2024
  • Table 10: Europe Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2014-2024
  • Table 11: Europe Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2014-2024
  • Table 12: Europe Plasma Protein Therapeutics Market Revenue, by Countries, (US$ Mn), 2014-2024
  • Table 13: Asia Pacific Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2014-2024
  • Table 14: Asia Pacific Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2014-2024
  • Table 15: Asia Pacific Plasma Protein Therapeutics Market Revenue by Countries, (US$ Mn), 2014-2024
  • Table 16: LATAM Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2014-2024
  • Table 17: LATAM Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2014-2024
  • Table 18: Latin America Plasma Protein Therapeutics Market Revenue, by Countries, (US$ Mn), 2014-2024
  • Table 19: ROW Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2014-2024
  • Table 20: ROW Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2014-2024
Back to Top